+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "T Cell Therapies"

Mesothelioma - Pipeline Insight, 2024 - Product Thumbnail Image

Mesothelioma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 210 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2024 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Anal Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Anal Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Paranasal sinus cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Paranasal sinus cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Adrenocortical Carcinoma - Pipeline Insight, 2024 - Product Thumbnail Image

Adrenocortical Carcinoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
LAG-3 Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

LAG-3 Antagonist - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
TIGIT inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

TIGIT inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Histone deacetylase (HDAC) Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Histone deacetylase (HDAC) Inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
PI3K inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

PI3K inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
4-1BB receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

4-1BB receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
CD137 Agonist Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

CD137 Agonist Antibody - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Inhibitor Of Apoptosis (IAP) Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
T Cell Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

T Cell Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
From
Loading Indicator

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more